Document Detail


Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation.
MedLine Citation:
PMID:  19889728     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
GVHD is a major barrier to broader use of allogenic HSCT for nonmalignancy clinical applications such as the treatment of primary immunodeficiencies and hemoglobinopathies. We show in a murine model of C57BL/6J (H2-k(b)) --> B6D2F1/J (H2-k(b/d)) acute GVHD that when initiated 2 days before transplant, the activation of the adenosine A(2A)R with the selective agonist ATL146e inhibits the weight loss and mortality associated with disease progression. Furthermore, circulating levels of proinflammatory cytokines and chemokines, including IFN-gamma, IL-6, CCL2, KC, and G-CSF, are reduced significantly by 14-day ATL146e treatment. The up-regulation of CD25, CD69, and CD40L expression by donor CD4(+) and CD8(+) T cells is inhibited by A(2A)R activation; fewer CD3(+) T cells are found in the liver, skin, and colon of ATL146e-treated mice as compared with vehicle-treated controls; and associated tissue injury is lessened. The delayed administration of ATL146e, beginning 9 days after HSCT, reverses GVHD-associated body weight loss successfully, and improvement is sustained for the duration of treatment. We conclude that the selective activation of the A(2A)R has therapeutic potential in the prevention and treatment of acute GVHD.
Authors:
Courtney M Lappas; Po-Ching Liu; Joel Linden; Elizabeth M Kang; Harry L Malech
Related Documents :
10871148 - T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic ...
21063028 - Pd-l1 blockade effectively restores strong graft-versus-leukemia effects without graft-...
2188738 - Phenotypic analysis of the early events during repopulation of the thymus by the bone m...
14628078 - Donor commitment and patient needs.
14977478 - Artificial niches for human adult neural stem cells: possibility for autologous transpl...
18249448 - Sorting vector producer cells for high transgene expression increases retroviral titer.
Publication Detail:
Type:  Journal Article     Date:  2009-11-04
Journal Detail:
Title:  Journal of leukocyte biology     Volume:  87     ISSN:  1938-3673     ISO Abbreviation:  J. Leukoc. Biol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-03     Completed Date:  2010-02-25     Revised Date:  2011-07-22    
Medline Journal Info:
Nlm Unique ID:  8405628     Medline TA:  J Leukoc Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  345-54     Citation Subset:  IM    
Affiliation:
Department of Biology, Lebanon Valley College, Annville, Pennsylvania, USA. lappas@lvc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adenosine A2 Receptor Agonists
Animals
Antigens, CD / immunology
CD4-Positive T-Lymphocytes / immunology*,  pathology
CD8-Positive T-Lymphocytes / immunology*,  pathology
Cyclohexanecarboxylic Acids / pharmacology
Cytokines / immunology
Disease Models, Animal
Female
Gene Expression Regulation / drug effects,  immunology
Graft vs Host Disease / drug therapy,  immunology*,  pathology
Hematopoietic Stem Cell Transplantation*
Mice
Purines / pharmacology
Receptor, Adenosine A2A / immunology*
Transplantation, Homologous
Chemical
Reg. No./Substance:
0/ATL 146e; 0/Adenosine A2 Receptor Agonists; 0/Antigens, CD; 0/Cyclohexanecarboxylic Acids; 0/Cytokines; 0/Purines; 0/Receptor, Adenosine A2A
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The adaptor protein p66shc is a positive regulator in the angiogenic response induced by hypoxic T c...
Next Document:  Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils.